Company intelligence / Profile preview
Selexel
- Ownership
- Private
- Development stage
- Other
Overview
Selexel is a French biotechnology company developing therapeutic solutions in oncology using innovative RNA interference technologies. Its lead programs are in preclinical development and focus on neoplasms, with one program targeting the androgen receptor pathway for castration-resistant prostate cancer. No clinical results have been reported as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small interfering RNASmall molecule
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Selexel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selexel.